Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05122559 · ClinicalTrials.gov registry record · Phase 2
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
A Phase 2 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive, sponsored by Emmanuelle Waubant, MD PhD.
- Active
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
- 1
- Study location
NCT05122559: Active Phase 2 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive, sponsored by Emmanuelle Waubant, MD PhD.
NCT05122559 is a Phase 2 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive that is active but no longer recruiting, run by Emmanuelle Waubant, MD PhD. The registered enrollment target is 98 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05122559, a Phase 2 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive, is active but no longer recruiting, sponsored by Emmanuelle Waubant, MD PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
Primary Outcome
Number of adverse events recorded by system, severity, and by relationship to treatment arm.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG N-acetyl cysteine
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What the registry record for NCT05122559 still lists
NCT05122559 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05122559 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05122559 about?
NCT05122559 is a clinical study titled "Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis". This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
What is the current status of trial NCT05122559?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2022-02-16. Estimated completion is 2027-02.
What conditions does trial NCT05122559 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive.
What interventions are being tested in trial NCT05122559?
The interventions under investigation include: Placebo (DRUG), N-acetyl cysteine (DRUG).
Who is sponsoring clinical trial NCT05122559?
This trial is sponsored by Emmanuelle Waubant, MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05122559 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05122559's enrollment target sits among peer trials
98 136th of 315 higher than 180 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI